Radisys Announces Availability of Industry-first Release 17 Compliant 5G NR Solution
22.2.2023 16:00:00 EET | Business Wire | Press release
Radisys® Corporation, a global leader of open telecom solutions, today announced its Release 17 compliant 5G NR software solution, extending its award-winning Release 16 Software with advanced features like non-terrestrial networks (NTN) and integrated access and backhaul (IAB) that expands coverage ability for 5G Networks. Release 17 relay node and satellite access capabilities will improve worldwide cellular service availability by enhancing the accessibility of fast and reliable 5G connectivity for unserved and underserved areas. In addition to driving ubiquitous 5G consumer access, Radisys’ Release 17 compliant 5G NR software supports enterprise, infrastructure and public safety use cases including intelligent transportation systems (ITS), aeronautic broadband, maritime, critical communications, fleet management, smart factories, and Internet of Things (IoT) devices.
Radisys’ Connect RAN 5G solution facilitates a flexible 5G network to meet varied deployment requirements and provide universal 5G connectivity for diverse applications and use cases. By deploying Connect RAN 5G software, customers can minimize their development costs and operational and capital expenses while at the same time improving time-to-market and shortening their return on investment.
News Highlights
- Radisys’ Release 17 compliant RAN software continues its proven track record of 5G R&D innovation, enabling 5G Network connectivity for diverse service enabler ultra-reliable low latency communication (URLLC), and eMBB use cases across a wide set of FR1and FR2 bands for multiple deployment and access options.
- Radisys’ Connect RAN 5G software’s NTN feature supports geostationary, medium and low earth orbit (GEO/MEO/LEO) satellite access with flexible and scalable software architecture and well-defined interfaces to SATCOM infrastructure. Radisys’ NTN software empowers OEMs and ODMs to unlock newer business opportunities by leveraging the significant investment being made in SATCOM technology.
- Radisys’ IAB feature enhances centralized (CU) and distributed (DU) units to service relay nodes as 3GPP compliant Donor CUs and Donor DUs. It also includes IAB/Relay node comprising IAB-DU and IAB-MT software that provides end-to-end IAB solution integration with industry-leading platforms.
- Radisys’ Release 17 compliant RAN software provides a foundation for features such as NR positioning, reduced capability (RedCap), and NR SideLink enabling OEMs, ODMs and operators to cost-effectively scale their 5G networks.
“We are excited to launch the first-to-market Release 17 Connect RAN 5G Software delivering expanded 5G connectivity and service accessibility, enabling our customers to unlock newer business opportunities,” said Munish Chhabra, SVP and General Manager, Software and Services, Radisys. “With advanced features like NTN and IAB, Radisys continues to be a leader in delivering ORAN-compliant multi-architecture and multi-platform 5G software to our customers, driving business use cases across a variety of industry verticals.”
Meet with Radisys at MWC Barcelona
See demonstrations of Radisys’ industry-first Release 17 compliant 5G NR Solution, at MWC Barcelona, Stand 5B81. To schedule a meeting with Radisys’ mobility experts, contact open@radisys.com.
About Radisys
Radisys is a global leader in open telecom solutions and services. Its disaggregated platforms and integration services leverage open reference architectures and standards combined with open software and hardware, enabling service providers to drive open digital transformation. Radisys offers an end-to-end solutions portfolio from digital end points, to disaggregated and open access and core solutions, to immersive digital applications and engagement platforms. Its world-class and experienced network services organization delivers full lifecycle services to help service providers build and operate highly scalable and high-performance networks at optimum total cost of ownership. For more information, visit www.Radisys.com.
Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230222005290/en/
Contact information
Nereus for Radisys
Matt Baxter, +1-503-619-0505
radisys@nereus-worldwide.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom